lenalidomide – Medxy AI

Targeting Post-Transplant Myeloid Immune Suppression in Multiple Myeloma: Why CSF-1R Blockade May Enhance Lenalidomide Maintenance After ASCT

By MedXY 06/08/2026

A new Blood study links relapse after myeloma ASCT to CSF-1R+ immunosuppressive marrow macrophages and shows that CSF-1R inhibition synergizes with lenalidomide in preclinical models, providing a strong translational rationale for post-transplant combination maintenance.

$Lenalidomide-Rituximab vs. Lenalidomide-Rituximab-Bendamustine in Relapsed/Refractory Follicular Lymphoma: A Phase II Showdown$

Hematology-Oncology news

Lenalidomide-Rituximab vs. Lenalidomide-Rituximab-Bendamustine in Relapsed/Refractory Follicular Lymphoma: A Phase II Showdown

By MedXY 04/21/2026

The HOVON110/ReBeL study compares R2 and R2B regimens in R/R FL, revealing comparable efficacy but higher toxicity with bendamustine addition. Despite low CT-based CR rates, R2B showed numerically better EFS and OS.

Hematology-Oncology news Oncology Specialties

Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen

By MedXY 10/15/2025

The IFM2017-03 phase 3 trial demonstrates that a dexamethasone-sparing regimen combining daratumumab with lenalidomide markedly improves progression-free survival in frail elderly multiple myeloma patients, without increasing serious adverse events.

Clinical Updates Hematology-Oncology news Specialties

Novel Efficacy and Safety of Obinutuzumab Combined with Lenalidomide in First-Line Treatment of High Tumor Burden Follicular Lymphoma

By MedXY 08/30/2025

This phase 2 study demonstrates that obinutuzumab plus lenalidomide achieves high response rates with durable progression-free survival and manageable toxicities in untreated high tumor burden follicular lymphoma, suggesting a promising frontline option.

Clinical Updates Hematology-Oncology news Specialties

Optimizing Therapy in Transplant-Ineligible Multiple Myeloma: Insights from the REST Phase 2 Trial on Isatuximab, Bortezomib, Lenalidomide, and Limited Dexamethasone

By MedXY 08/30/2025

The REST trial demonstrated that combining isatuximab with weekly bortezomib, lenalidomide, and limited dexamethasone yields promising efficacy and manageable safety in older patients with transplant-ineligible multiple myeloma.

Clinical Updates Hematology-Oncology news Specialties

Carfilzomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Multiple Myeloma: High MRD Negativity and PFS Benefit in the EMN20 Trial

By MedXY 08/07/2025

The EMN20 phase 3 trial demonstrates that adding carfilzomib to lenalidomide-dexamethasone significantly increases MRD negativity and progression-free survival in transplant-ineligible newly diagnosed multiple myeloma, with manageable toxicity.